Axsome Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Axsome Therapeutics (AXSM).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

20Buy

Consensus RatingBuy# Analysts20Avg. Consensus PT$239Upside to Avg. PT+41.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$297→$295
Sep 29, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$280→$267
Sep 25, 2026	Morgan Stanley	Sean Laaman	PT Cut	Equal-Weight	$251→$247
Sep 23, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$200→$285
Sep 18, 2026	Piper Sandler	David Amsellem	Maintained	Overweight	$258
Aug 31, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Aug 12, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$306→$316
Aug 11, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$242→$251
Aug 11, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$304→$297
Aug 11, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$260→$275
Aug 11, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$255→$256
Aug 11, 2026	Needham	Ami Fadia	PT Raise	Buy	$267→$268
Jul 31, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$310→$306
Jul 21, 2026	BMO Capital	Malcolm Hoffman	Initiate	Outperform	$310
Jul 15, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Jul 8, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$290
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$302→$304
Jun 17, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$275→$300
May 5, 2026	Morgan Stanley	Sean Laaman	PT Raise	Equal-Weight	$217→$242
May 5, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$242→$302

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.

Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.

Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.

Avi Kapoor

PRO
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.

Benzinga Newsdesk

Axsome Therapeutics Inc

Axsome Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PRO
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

People Also Watch

People Also Watch

Axsome Therapeutics Inc

Axsome Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRODeutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PROMorgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PROTruist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PROPiper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

PRO
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

PRO
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

PRO
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285

PRO
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target